2025 Japan Antisense And Rnai Therapeutics Market Revenue Opportunities Report
Description
The 2025 Japan Antisense And Rnai Therapeutics Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antisense and RNAi therapeutics market in Japan are Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Sanofi, and GSK plc. Alnylam has collaborations in Japan, such as with Chugai Pharmaceutical for RNAi therapeutic commercialization and expanding partnerships across Asia Pacific. Ionis is notable for its global development deals and ongoing clinical studies, including partnerships targeting conditions prevalent in Japan. Sanofi and GSK are prominently listed among key players with a strong presence and involvement in advancing antisense and RNAi therapies globally and within Japan.
Japan's market for these therapies is rapidly growing, driven by the aging population and a strong focus on personalized medicine. The RNA interference segment leads revenue generation and growth, with Japan expected to expand at a CAGR of 18.2% from 2025 to 2030, reaching an estimated market size of USD 776.3 million by 2030. These companies capitalize on regulatory approvals and strategic partnerships within Japan to meet increasing demand for treatments addressing genetic, cardiovascular, neurological, and liver diseases.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antisense and RNAi Therapeutics Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antisense and RNAi therapeutics market in Japan are Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Sanofi, and GSK plc. Alnylam has collaborations in Japan, such as with Chugai Pharmaceutical for RNAi therapeutic commercialization and expanding partnerships across Asia Pacific. Ionis is notable for its global development deals and ongoing clinical studies, including partnerships targeting conditions prevalent in Japan. Sanofi and GSK are prominently listed among key players with a strong presence and involvement in advancing antisense and RNAi therapies globally and within Japan.
Japan's market for these therapies is rapidly growing, driven by the aging population and a strong focus on personalized medicine. The RNA interference segment leads revenue generation and growth, with Japan expected to expand at a CAGR of 18.2% from 2025 to 2030, reaching an estimated market size of USD 776.3 million by 2030. These companies capitalize on regulatory approvals and strategic partnerships within Japan to meet increasing demand for treatments addressing genetic, cardiovascular, neurological, and liver diseases.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
